文献速递浆细胞疾病

高危冒烟型骨髓瘤患者的基线突变模式与持续MRD阴性

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
PubMed 文献 · Blood Adv · 2017-09-29

这项前瞻性2期试验扩展队列纳入18例高危冒烟型骨髓瘤患者,接受卡非佐米、来那度胺和地塞米松诱导后来那度胺维持治疗,总缓解率100%,中位潜在随访43.3个月时10例(63%)维持MRD阴性,估计4年无进展生存率和总生存率分别为71%和100%;与平行试验新诊断多发性骨髓瘤参照组相比,高危冒烟型骨髓瘤患者重要骨髓瘤基因突变频率(6.6% vs 45%)和NFKB通路基因突变频率(6.6% vs 25%)更低。

要点

  • 高危冒烟型骨髓瘤患者接受卡非佐米、来那度胺和地塞米松后来那度胺维持,总缓解率100%。
  • 中位潜在随访43.3个月,10例(63%)维持MRD阴性,估计4年PFS率71%、OS率100%。
  • 高危冒烟型骨髓瘤重要骨髓瘤基因突变频率6.6% vs 新诊断多发性骨髓瘤45%,NFKB通路基因6.6% vs 25%。

核心结论

  • 卡非佐米、来那度胺和地塞米松后来那度胺维持治疗与100%缓解率和63% MRD阴性相关,安全性特征与既往报道一致。
  • 高危冒烟型骨髓瘤与新诊断多发性骨髓瘤的基因 landscape 存在差异,提示早期疾病生物学上对治疗更敏感。

研究设计与样本

  • 前瞻性2期临床试验的扩展队列,2012年5月29日至2014年1月14日入组18例高危冒烟型骨髓瘤患者。
  • 参照组为平行试验中接受相同治疗的新诊断多发性骨髓瘤患者。

主要发现

  • 总缓解率为100%。
  • 中位潜在随访43.3个月时,10例(63%)维持MRD阴性,估计4年无进展生存率为71%,总生存率为100%。
  • 高危冒烟型骨髓瘤患者重要骨髓瘤基因突变频率为6.6%,新诊断多发性骨髓瘤参照组为45%。
  • 高危冒烟型骨髓瘤患者NFKB通路基因突变频率为6.6%,新诊断多发性骨髓瘤参照组为25%。

关键数值与推荐

  • 高危冒烟型骨髓瘤患者重要骨髓瘤基因突变频率6.6% vs 新诊断多发性骨髓瘤参照组45%。
  • 高危冒烟型骨髓瘤患者NFKB通路基因突变频率6.6% vs 新诊断多发性骨髓瘤参照组25%。
  • 中位潜在随访43.3个月时MRD阴性率为63%(10例)。
  • 估计4年无进展生存率为71%,总生存率为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究参与者数量少。
  • 高危冒烟型骨髓瘤与新诊断多发性骨髓瘤的基因 landscape 差异似乎重要,但需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results that were previously published. Here, we provide novel insights into the genetic landscape of high-risk smoldering myeloma and information on sustained minimal residual disease (MRD) negativity with an expanded cohort of patients. Eighteen patients with high-risk smoldering myeloma were enrolled between 29 May 2012, and 14 January 2014. We included patients with newly diagnosed multiple myeloma enrolled in a parallel trial who received the same therapy (reference group). The overall response rate was 100%. With median potential follow-up of 43.3 months, 10 (63%) remain in MRD negativity, and the estimated 4-year progression-free and overall survival rates are 71% and 100%, respectively. Importantly, we report differences in mutational patterns in patients with high-risk smoldering myeloma and newly diagnosed multiple myeloma, reflected in a lower frequency of mutations in significant myeloma genes (6.6% vs 45%) and NFKB pathway genes (6.6% vs 25%). Treatment with carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance was associated with a 100% response rate and 63% MRD negativity with a safety profile consistent with previous reports for this regimen. This study had a small numbers of participants, but there seemed to be important differences in the genetic landscape of patients with high-risk smoldering myeloma and those with newly diagnosed multiple myeloma, suggestive of a more treatment-responsive biology in early disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mailankody S, Kazandjian D, Korde N, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv. 2017. PMID: 29296837. doi:10.1182/bloodadvances.2017005934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。